Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 10/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122460 | 0.96 | CTSC (0.55) | CTSCBRD4EGFRJAK3JAK2 | |
| Formic Acid SCHEMBL14482025 | 0.94 | CTSC (0.54) | CTSCBRD4EGFRJAK3JAK2 | |
| Formic Acid SCHEMBL14481828 | 0.93 | JAK1 (0.54) | CTSCBRD4JAK3JAK2CYP3A4 | |
| SCHEMBL3108564 | 0.91 | CTSC (0.57) | CTSCBRD4EGFRJAK3JAK2 | |
| SCHEMBL3118310 | 0.89 | JAK1 (0.57) | CTSCBRD4JAK3JAK2CYP3A4 | |
| SCHEMBL3112812 | 0.88 | BRD4 (0.61) | CTSCBRD4EGFRJAK3JAK2 | |
| Formic Acid SCHEMBL14482084 | 0.88 | CTSC (0.52) | CTSCBRD4EGFRJAK3JAK2 | |
| SCHEMBL12854649 | 0.87 | CTSC (0.58) | CTSCBRD4EGFRJAK3JAK2 | |
| Formic Acid SCHEMBL15388293 | 0.86 | BRD4 (0.57) | CTSCBRD4EGFRJAK3JAK2 | |
| SCHEMBL3109342 | 0.84 | CTSC (0.56) | CTSCBRD4EGFRJAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | CTSC 2302/4885BRD4 758/4885EGFR 1807/4885 |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | CTSC 2302/4885BRD4 758/4885EGFR 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.